Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Initiates Phase 1 Clinical Trial for Anti-RSPO3 Antibody

REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics,...
July 06, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present at the Cantor Fitzgerald Inaugural Healthcare Conference

REDWOOD CITY, Calif., July 6, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
June 29, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Appoints Rick Winningham to Board of Directors

REDWOOD CITY, Calif., June 29, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc., (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics,...
June 01, 2015 09:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting

Demcizumab plus Abraxane and Gemcitabine in Advanced Pancreatic Cancer Results in 50% Response Rate, Progression-Free Survival of 9.0 Months and Overall Survival of 10.1 Months Randomized Phase 2...
June 01, 2015 09:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Phase 1b Clinical Trial Data for Tarextumab in Small Cell Lung Cancer at the 2015 ASCO Annual Meeting

CHICAGO, June 1, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) presented new survival and biomarker data and updated clinical response and safety results from its Phase 1b...
June 01, 2015 09:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting

40% of Patients Receiving Continuous Dosing of Demcizumab plus Standard Chemotherapy Alive at Two Years New Biomarker Data May Support Prolonged Survival Observations in Subset of...
May 28, 2015 16:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present at Upcoming Investment Conferences

REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
May 28, 2015 16:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab and Tarextumab During Conference Call on Tuesday, June 2, 2015

REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
May 14, 2015 16:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present at UBS Global Healthcare Conference

REDWOOD CITY, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
May 07, 2015 16:05 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Announces First Quarter 2015 Financial Results

REDWOOD CITY, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) today reported financial results for the quarter ended March 31, 2015 and provided an update on...